Biologics

Child with eczema
#Atopic dermatitis #Biologics #Dermatology #Eczema #Monoclonal antibodies

First biologic therapy for young children with severe eczema

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal… Read More

#News

Biologics
#Biologics #Characterisation #Formulation

App note – Light scattering measurements for biologics

The ability to monitor biologic candidates’ propensity towards self-association is critical for predicting whether a therapeutic is likely to aggregate or become difficult to administer due to viscosity. In this app note, read how Merck KGaA uses light scattering measurements to predict how formulations will behave at clinically relevant… Read More

#News

Monoclonal antibody
#Biologics #Biopharma #Drug development

New ebook: The researcher’s guide to Dynamic Light Scattering

This e-book by NanoTemper looks at the workflows researchers are using in the biologics space and the benefits dynamic light scattering (DLS) offers. You will find out: What biologics are and why they’re important How DLS gives you information about your samples and what that data means Tips and… Read More

#News

#Automation / robotics #Biologics #Process analytical technology

Listicle: Driving production in biologics with automation 

Drug development technology has evolved rapidly in recent years, and with the industry advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. The significance of biologics is far-reaching, including treatment of rheumatologic diseases, cancer, diabetes and anaemia. The range of… Read More

#Editor's Choice #Listicles #Videos

#Automation / robotics #Biologics #Biopharma #Drug development

Driving production in biologics development with automation

Drug development technology has evolved rapidly in recent years, and with the industry, advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. Since most biologics are large molecules, they may prove challenging to develop and manufacture on the large scale. Read More

#News

Human liver
#Biologics #Liver cancer #Oncology

AstraZeneca’s liver cancer therapy gets accepted for review  

AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, the company has announced. Tremelimumab is a human monoclonal antibody which AstraZeneca is investigating as a potential therapy for cancers. It works by targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Now, tremelimumab… Read More

#News

#Biologics #Drug discovery

With biologic drug discovery mounting, CAS announces expansion 

CAS, a division of the American Chemical Society specialising in scientific information solutions, has launched an expansion of the CAS SciFinder Discovery Platform into life sciences. The enhanced platform includes over two million modified biosequences, 60 years of patent literature, and one of the largest collections of journal information… Read More

#News

#Biologics #Biotechnology #Pharmaceuticals #Research

Sino Biological establishes new location in Texas 

Sino Biological, provider of biological research reagents and related technical contract research services, has expanded to a new location in Houston, Texas.  The company has headquarters in Beijing, China and subsidiaries in Suzhou (China), Taizhou (China), Frankfurt (Germany), and Wayne (Pennsylvania, US). The new location in Houston allows for… Read More

#News

#Antibody #Biologics #Biosciences #Drug discovery

Twist Bioscience acquires Abveris to bolster biopharma capabilities  

Twist Bioscience has acquired Abveris, which will offer Twist comprehensive antibody discovery and characterisation services using its DiversimAb family of hyperimmune mouse models, the output of which can be humanised using the Twist antibody optimisation solution to develop biologics for rapid clinical advancement.   Emily Leproust, CEO and co-founder of Twist Bioscience, believes that the addition of the Abveris discovery… Read More

#News

#Biologics #Drug development #Drug discovery #Immuno-oncology #Monoclonal antibodies

The potential of small molecules and biologics for new therapeutics 

Listen to this article on the DDW Podcast: Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals has harnessed the power of clinical… Read More

#Business & Investment #Exclusive Content #News

#Biologics #Drug development #Flow Cytometry #Immunogenicity #Therapeutics

Cellular assays to bridge the gap in immunogenicity prediction 

Listen to this article on the DDW Podcast: Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development.  Biologic drugs as therapy have improved the treatment of many diseases, but their success is often tempered by antidrug antibodies (ADAs),… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Antibodies #Antibody libraries #Biologics #Biopharmaceuticals #DNA #Drug discovery #Drug targets #Screening

Newly launched antibody libraries put hard-to-drug targets within reach

Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Antivirals #Biologics #Biopharmaceuticals #Collaboration #Covid-19 #Laboratory data

This week in drug discovery (1-5 November) 

News round-up by DDW’s Megan Thomas for 1-5 November DDW’s Megan Thomas has selected five stories which showcase the international scope of the drug discovery industry in terms of research, innovation, collaboration and development. 1. New consortium to boost Covid-19 vaccine production in South Africa The Medicines Patent… Read More

#News #Trending News

#Biologics #Cell and gene therapy #Cobra Biologics #DNA

Swedish government and industry to boost product partnerships 

Flerie Invest led a syndicate of investors in the $52 million acquisition of Cobra Biologics, Charles River Laboratories’ DNA and protein manufacturing subsidiary in Sweden. The new entity, NorthX Biologics, will take over and expand the facility, which is equipped to provide GMP-grade plasmid DNA and technical protein manufacture at commercial scale.   Ibrahim Baylan,… Read More

#News #Trending News #Trends & Analysis

#Biologics #Drug discovery #Drug therapy #Events #Immunotherapy

Two-day biologics drug discovery course open for registration 

Join Terrence Kenakin as he presents a two-day Applied course on September 21 and September 22 at 10AM CDT.   This two-day course will introduce the topic of biologics as a drug therapy in addition to recombinant replacement protein biologics, peptide signalling, immunotherapy, antibodies features, and nucleotide-based… Read More

#News